The latest research study released by Transparency Market Research on “Anti-Infective Drugs Market Forecast to 2023-2031 ″ research provides accurate economic, global, and country-level predictions and analyses. It provides a comprehensive perspective of the competitive market as well as an in-depth supply chain analysis to assist businesses in identifying major changes in industry practices. The market report also examines the current state of the Anti-Infective Drugs industry, as well as predicted future growth, technological advancements, investment prospects, market economics, and financial data.
Anti-Infective Drugs market is estimated to attain a valuation of US$ 177.9 Bn by the end of 2031, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 4% during the forecast period, 2023-2031
Get a Sample Copy of the Anti-Infective Drugs Market Research Report (Use Corporate Mail Id for Quick Response) –https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=41204
“Connect with our team of research specialists and unlock the optimal solution for driving your business growth”
High prevalence of viral diseases and rise in awareness about infectious diseases and their treatment options among consumers are key factors driving the global market. Growth in government funding to enhance drug approvals is also boosting the anti-infective drugs market revenue. Furthermore, increase in R&D and technological advancements are augmenting the market.
Manufacturers are concentrating on new product launches, approvals, and collaborations to gain value-grab anti-infective drugs market opportunities. Anti-infective drug companies are focusing on expanding their production capacity post the peak of the COVID-19 pandemic. Government organizations such as the WHO and UNICEF are also increasing funding to enhance product approvals. However, side-effects associated with anti-infective drugs and shortage of resources in certain low- and middle-income countries (LMIC) are likely to restrain market growth in the near future.
Updated Version of Sample Report Included:
- Detailed industry forecast
- Brief Introduction to the research report.
- Additional information on company participants
- Customized reports and analyst assistance are available upon request.
- Recent market developments and potential future growth opportunities
- Personalized regional/country reports upon request
- New data sources are being integrated.
- Increased focus on data privacy and security
- Increased collaboration and co-creation
Inquire more about this report before purchase – https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=41204
Market Introduction
Anti-infective drugs are medications used to treat or prevent infections caused by bacteria, viruses, fungi, or parasites. These drugs can work in various ways, such as by killing the infectious organism or by inhibiting its growth and replication.
Common examples of anti-infective drugs include antibiotics, antivirals, antifungals, and antiparasitics. Antibiotics are used to treat bacterial infections in patients, while antivirals are used to treat viral infections. Antifungals help treat fungal infections, whereas antiparasitics are used to treat parasitic infections.
Tuberculosis (TB) is the world’s second-largest infectious disease after COVID-19. In 2020, TB accounted for an estimated 1.5 million deaths (including people with HIV). After South Africa, India is the leading country with high prevalence of HIV/AIDS worldwide.
New infectious diseases such as avian flu and swine flu are also emerging at a higher rate and spreading more rapidly than ever in communities. Thus, the global demand for anti-infective drugs is expected to increase during the forecast period.
Growth in government initiatives to create awareness about infectious diseases and their treatment options is a key factor fueling the anti-infective drugs market expansion. Governments of several countries are increasingly investing in laboratory infrastructure and diagnostic capacities.
As per an article published by the Centers for Disease Control and Prevention (CDC), in September 2021, the Biden-Harris administration invested US$ 2.1 Bn to improve infection prevention and control activities across the U.S. public health and healthcare sector.
Rise in investment in R&D activities of anti-infective drugs due to surge in various new infectious diseases, such as COVID-19, is driving the global market. In 2019, the pharmaceutical sector invested US$ 83.0 Bn in R&D of anti-infective drugs.
Competitor Analysis:
The significant players operating in the global Anti-Infective Drugs market are
Pfizer Inc., Gland Pharma Ltd., Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd., Novartis AG, Gilead Sciences, Inc., GlaxoSmithKline plc, Merck & Co., Inc., Abbott, Astellas Pharma Inc., Alkem Laboratories, AstraZeneca, Eli Lilly and Company, Johnson & Johnson Services, Inc., Takeda Pharmaceutical Company Limited, and Sanofi
Market Segmentation –
- Drug Class
- Antibacterials
- B-lactams
- Quinolones
- Macrolides
- Tetracycline
- Aminoglycoside
- Others (Phenicols, Sulfonamides, etc.)
- Antivirals
- Miscellaneous Antivirals
- Adamantane Antivirals
- Antiviral Boosters
- Others (Antiviral Combinations, Antiviral Interferons, etc.)
- Antifungals
- Azoles
- Echinocandins
- Polyenes
- Others
- Others (Antiparasitics, Anthelmintics, etc.)
- Antibacterials
- Route of Administration
- Oral
- Parenteral
- Others (Topical, etc.)
- Indication
- Pneumonia
- Sepsis
- Tuberculosis
- Influenza
- HIV Infection
- Hepatitis Virus Infection
- Respiratory Virus Infection
- Others (Aspergillosis, Candidiasis, Dermatophytosis, etc.)
- Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
This Report lets you identify the opportunities in Anti-Infective Drugs Market by means of a region:
- North America (the United States, Canada, and Mexico)
- Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
- Asia-Pacific (China, Japan, Korea, India, Australia, and Southeast Asia (Indonesia, Thailand, Philippines, Malaysia, and Vietnam))
- South America (Brazil etc.) The Middle East and Africa (North Africa and GCC Countries)
Have Any Query? Ask To Analyst: https://www.transparencymarketresearch.com/sample/sample.php?flag=ASK&rep_id=41204
Key Developments
- In May 2023, the U.S. FDA approved the oral antiviral Paxlovid for the treatment of COVID-19 in adults. Paxlovid is the fourth drug and the first oral antiviral pill approved by the FDA for COVID-19.
- In November 2022, Shionogi & Co., Ltd. reported that Xocova obtained emergency regulatory approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for the indication of SARS-CoV-2 infection. Xocova is a novel anti-SARS-CoV-2 drug for COVID-19.
Research Methodology
The report has its roots definitely set in thorough strategies provided by proficient data analysts. The research methodology involves the collection of information by analysts only to have them studied and filtered thoroughly in an attempt to provide significant predictions about the market over the review period. The research process further includes interviews with leading market influencers, which makes the primary research relevant and practical. The secondary method gives a direct peek into the demand and supply connection. The market methodologies adopted in the report offer precise data analysis and provide a tour of the entire market. Both primary and secondary approaches to data collection have been used. In addition to these, publicly available sources such as annual reports, and white papers have been used by data analysts for an insightful understanding of the market.
Reasons to Buy The Anti-Infective Drugs Market Report: –
1.Regional report analysis highlighting the consumption of products/services in a region also shows the factors that influence the market in each region.
2.Reports provide opportunities and threats faced by suppliers in the Anti-Infective Drugs industry around the world.
The report shows regions and sectors with the fastest growth potential.
3.A competitive environment that includes market rankings of major companies, along with new product launches, partnerships, business expansions, and acquisitions.
4.The report provides an extensive corporate profile consisting of company overviews, company insights, product benchmarks, and SWOT analysis for key market participants.
5.This report provides the industry’s current and future market outlook on the recent development, growth opportunities, drivers, challenges, and two regional constraints emerging in advanced regions.
More Trending Reports by Transparency Market Research –
Sports Betting Market to Rise at a CAGR of 9.1% during Forecast Period
Shop Fitting Materials Market to Grow at a CAGR of 4.5% from 2023 to 2031, Reaching US$ 234.1 Billion
About Us Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.
Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.
Contact Us
Nikhil Sawlani
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453